98%
921
2 minutes
20
Background: Measurement with a lipid panel after statin initiation and in long-term follow-up is recommended in both 2013 and 2018 cholesterol guidelines to assess statin efficacy and adherence. We assessed whether routine laboratory evaluation with lipid panels is associated with greater statin adherence.
Methods: We identified patients with atherosclerotic cardiovascular disease within the entire Veterans Affairs (VA) health care system with at least one primary care visit between October 2013 and September 2014, who were on statin therapy (n = 813,887; n = 52,583 for new statin users). Statin adherence was determined using medication refill data and assessed by proportion of days covered (PDC). Association between number of lipid panels completed and PDC was assessed with adjusted regression models.
Results: Within the study period, the mean number of lipid panels that were completed per patient was 1.5 ± 1.0. In the overall cohort, percentage of statin users with PDC ≥80% was 66.0% for patients with ≥1 lipid panel and 61.2% for patients with 0 lipid panels (P < .0001). Among new statin users, PDC ≥80% was 68.0% for patients with lipid panels completed within 4-12 weeks of therapy initiation and 59.3% for those without lipid panels completed within the timeframe (P < .0001). In adjusted analysis, number of lipid panels completed was associated with a modest but significant increase in PDC, when PDC was evaluated as a continuous (beta-coefficient 0.0054, P < .001) or categorical (PDC ≥80% [odds ratio (OR) 1.01; 95% confidence interval (CI), 1.00-1.01]) measure of statin adherence. The significant association was also observed in new users (beta-coefficient 0.0058, P < .001; OR 1.02; 95% CI, 1.00-1.03).
Conclusion: Routine, guideline-directed completion of lipid panels in atherosclerotic cardiovascular disease patients on statins overall and among new statin users is associated with a modes6t but significant increase in statin adherence.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.amjmed.2019.04.002 | DOI Listing |
Introduction Systemic inflammation alters lipid metabolism by suppressing hepatic lipoprotein synthesis, increasing catabolism, and impairing reverse cholesterol transport. These changes result in reduced levels of low-density lipoprotein (LDL), high-density lipoprotein (HDL), and total cholesterol (TC), despite elevated cardiovascular risk, which is a phenomenon termed the "inflammatory lipid paradox." While well-characterized in chronic inflammatory diseases, such as rheumatoid arthritis, its prevalence and clinical impact in hospitalized adults with systemic inflammation remain underexplored.
View Article and Find Full Text PDFAppl Biochem Biotechnol
September 2025
Key Laboratory of Biofuels, Qingdao Institute of Bioenergy and Bioprocess Technology, Chinese Academy of Sciences, Qingdao, 266071, PR China.
High-ammonium wastewater can be simultaneously remediated and valorized through phototrophic cultivation of stress-resilient microalgae. This study evaluated the growth performance of 16 microalgae strains (specific growth rate μ = 0.108-0.
View Article and Find Full Text PDFExtracellular vesicles (EVs) are subcellular particles surrounded by a lipid bilayer membrane and incorporating various additional biomolecules derived from their donor cell. In many disease contexts circulating EVs have received increasing scientific attention due to their potential diagnostic and prognostic value. Additionally, EVs have been ascribed multiple biological functions, ranging from cellular waste disposal to sophisticated, intercellular communication.
View Article and Find Full Text PDFCureus
August 2025
Department of Pathology, Mahatma Gandhi Memorial Medical College, Indore, IND.
Introduction Psoriasis is a chronic, immune-mediated inflammatory skin disease with systemic manifestations. Among its significant comorbidities, metabolic syndrome (MS) - a constellation of obesity, hypertension, dyslipidemia, and insulin resistance - has gained recognition due to its association with increased cardiovascular risk and reduced life expectancy. Chronic systemic inflammation, shared immunological pathways, and elevated pro-inflammatory cytokines are thought to underlie this association.
View Article and Find Full Text PDFPrim Care Diabetes
October 2025
University of British Columbia, Vancouver, Canada.
This paper reports the expert opinions and recommendations made by primary care physicians (PCPs) to optimize screening and management of chronic kidney disease (CKD) associated with diabetes and presents algorithms to provide a practical and simplified guide for PCPs. Individuals living with type 2 diabetes (T2D) should be screened early and at regular intervals for CKD using both estimated glomerular filtration rate and urinary albumin-to-creatinine ratio testing. The risk of CKD assessed using the Kidney Disease: Improving Global Outcomes heatmap should be reviewed at least annually to optimize treatment to slow progression of CKD.
View Article and Find Full Text PDF